Source:http://linkedlifedata.com/resource/pubmed/id/17062005
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2007-2-12
|
| pubmed:abstractText |
Although liver transplantation (LTx) in HIV-positive patients receiving highly active antiretroviral therapy (HAART) has been successful, some have reported poorer outcomes in patients coinfected with hepatitis C virus (HCV). Here we discuss the impact of recurrent HCV on 27 HIV-positive patients who underwent LTx. HIV infection was well controlled post-transplantation. Survival in HIV-positive/HCV-positive patients was shorter compared to a cohort of HIV-negative/HCV-positive patients matched in age, model for end-stage liver disease (MELD) score, and time of transplant, with cumulative 1-, 3- and 5-year patient survival of 66.7%, 55.6% and 33.3% versus 75.7%, 71.6% and 71.6%, respectively, although not significantly (p = 0.07), and there was a higher likelihood of developing cirrhosis or dying from an HCV-related complication in coinfected subjects (RR = 2.6, 95% CI, 1.06-6.35; p = 0.03). Risk factors for poor survival included African-American race (p = 0.02), MELD score > 20 (p = 0.05), HAART intolerance postLTx (p = 0.01), and postLTx HCV RNA > 30000000 IU/mL (p = 0.00). Recurrent HCV in 18 patients was associated with eight deaths, including three from fibrosing cholestatic hepatitis. Among surviving coinfected recipients, five are alive at least 3 years after LTx, and of 15 patients treated with interferon-alpha/ribavirin, six (40%) are HCV RNA negative, including four with sustained virological response. Hepatitis C is a major cause of graft loss and patient mortality in coinfected patients undergoing LTx.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1600-6135
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
6
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2983-93
|
| pubmed:meshHeading |
pubmed-meshheading:17062005-Adult,
pubmed-meshheading:17062005-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:17062005-Female,
pubmed-meshheading:17062005-Graft Survival,
pubmed-meshheading:17062005-HIV Infections,
pubmed-meshheading:17062005-Hepatitis C,
pubmed-meshheading:17062005-Humans,
pubmed-meshheading:17062005-Liver Transplantation,
pubmed-meshheading:17062005-Male,
pubmed-meshheading:17062005-Middle Aged,
pubmed-meshheading:17062005-Postoperative Period,
pubmed-meshheading:17062005-Recurrence,
pubmed-meshheading:17062005-Survival Analysis,
pubmed-meshheading:17062005-Time Factors
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C.
|
| pubmed:affiliation |
Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. deverame@upmc.edu
|
| pubmed:publicationType |
Journal Article
|